Composition
Vilanterol (Ultra Long-Acting Beta2 Agonist – LABA)
Glycopyrronium (Long-Acting Muscarinic Antagonist – LAMA)
Fluticasone (Inhaled Corticosteroid – ICS)
This triple therapy helps open the airways, reduce inflammation, and improve lung function.
Therapeutic Uses
Doctors prescribe this inhaler for:
Chronic Obstructive Pulmonary Disease (COPD)
Severe persistent asthma (when appropriate)
Chronic bronchitis
Emphysema
Patients with frequent COPD exacerbations
Long-term respiratory maintenance therapy
Benefits for Respiratory Patients
Helps improve airflow
Reduces breathlessness
Controls airway inflammation
Reduces COPD flare-ups
Improves lung function
Enhances exercise tolerance
Helps reduce hospital admissions
Provides 24-hour bronchodilation
Convenient once-daily dosing (depending on the formulation)
Improves quality of life in chronic respiratory disease
Dosage & Administration
Use only as prescribed by a qualified physician.
The inhaler is intended for regular maintenance treatment and should not be used to relieve sudden breathing attacks.
Follow the inhalation technique recommended by your healthcare provider.
Do not exceed the prescribed daily dose.
Rinse your mouth after each use to help reduce the risk of oral fungal infection.
Precautions
Patients should inform their doctor if they have:
Heart disease
High blood pressure
Diabetes
Glaucoma
Enlarged prostate
Liver disorders
Pregnancy or breastfeeding
Active respiratory infections
Possible Side Effects
Dry mouth
Hoarseness
Cough
Headache
Sore throat
Oral fungal infection
Fast heartbeat
Muscle cramps
Tremors
Upper respiratory tract infection
Seek medical attention if severe allergic reactions or worsening breathing occur.
Why Healthcare Professionals Prefer Triple Therapy
Respiratory specialists often prescribe triple therapy for patients whose symptoms are not adequately controlled with dual therapy. The combination provides bronchodilation through two different mechanisms while reducing airway inflammation with an inhaled corticosteroid.
International Export Availability
Cordium Pharmaceuticals exports respiratory formulations to international pharmaceutical buyers while complying with applicable regulatory and import requirements in destination countries.
Major export markets include:
United States
United Kingdom
United Arab Emirates
South Africa
Saudi Arabia
Singapore
Australia
New Zealand
Kenya
Nigeria
Ghana
Tanzania
Qatar
Oman
Bahrain
Kuwait
Key cities with high demand for respiratory medicines
United States: New York, Los Angeles, Chicago, Houston, Miami, Boston, Philadelphia, Dallas
United Kingdom: London, Birmingham, Manchester, Liverpool, Leeds, Glasgow
United Arab Emirates: Dubai, Abu Dhabi, Sharjah, Ajman
South Africa: Johannesburg, Cape Town, Durban, Pretoria, Port Elizabeth
These regions have a significant burden of COPD and asthma, contributing to routine prescribing of advanced inhaled therapies by respiratory specialists.
Why Choose Cordium Pharmaceuticals?
Cordium Pharmaceuticals is committed to supplying quality pharmaceutical products for global healthcare markets.
Our strengths include:
Quality-assured manufacturing
International export support
Competitive pricing
Reliable documentation
Bulk supply capability
Distributor support
Timely shipments
Professional customer service
OEM and private-label options (where available)
Contact Cordium Pharmaceuticals
For export inquiries, distributor partnerships, and bulk orders:
📱 WhatsApp: +91-9405117673
📧 Email: info@cordiumpharma.com